Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01961232 · ClinicalTrials.gov registry record

Trans-pulmonary Biomarkers in Pulmonary Hypertension

A clinical trial of Pulmonary Hypertension, sponsored by Vanderbilt University.

Active
Registry status
100
Enrollment target
1
Study location

NCT01961232 is a study of Pulmonary Hypertension that is active but no longer recruiting, run by Vanderbilt University. The registered enrollment target is 100 participants, below the 612-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01961232, a study of Pulmonary Hypertension, is active but no longer recruiting, sponsored by Vanderbilt University.

ACTIVE NOT RECRUITING
Registry status
100 participants
Enrollment target
1
Study location

Study Summary

The investigators are testing whether the addition of Pulmonary Hypertension-related biomarkers, measured across the pulmonary circulation, to the standard hemodynamic evaluation for Pulmonary Hypertension will lead to more informed choices of Pulmonary Hypertension therapy and improved patient outcomes.

Conditions Studied

Study Locations (1)

Tennessee

  • Vanderbilt University Medical Center - Nashville

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2013-08
Est. Completion 2027-06

Sponsor

Vanderbilt University

430 total trials

What the Registry Record Tells You About NCT01961232

The ClinicalTrials.gov registry entry for NCT01961232 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 612-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (84% lower). The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pulmonary Hypertension appearing as the primary indexed condition, and to 0 interventions.

NCT01961232 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.

Frequently Asked Questions

What is clinical trial NCT01961232 about?

NCT01961232 is a clinical study titled "Trans-pulmonary Biomarkers in Pulmonary Hypertension". The investigators are testing whether the addition of Pulmonary Hypertension-related biomarkers, measured across the pulmonary circulation, to the standard hemodynamic evaluation for Pulmonary Hypertension will lead to more informed choices of Pulmonary Hypertension therapy and improved patient outc...

What is the current status of trial NCT01961232?

This trial is currently active not recruiting. The enrollment target is 100 participants. The study started on 2013-08. Estimated completion is 2027-06.

What conditions does trial NCT01961232 study?

This clinical trial studies the following conditions: Pulmonary Hypertension.

Who is sponsoring clinical trial NCT01961232?

This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01961232 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pulmonary Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.